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Abstract Familial hypercholesterolemia (FH) is an auto-
somal dominant disorder of lipoprotein metabolism caused
mainly by mutations in the low-density lipoprotein receptor
(LDLR) and apolipoprotein B 100 (APOB) genes. Until
now, the molecular basis of FH has been demonstrated in
detail in many populations, but there is still very limited
Molecular data concerning FH in Iran. The aim of this study
was to characterize the LDLR and APOB gene mutations in
an Iranian population. A total of 30 non-related Iranian
possible FH subjects were studied. Diagnosis of FH was
based on the Dutch Lipid Clinic Network diagnostic crite-
ria. All samples were initially tested for three common
APOB gene mutations including R3500Q, R3500 W and
R3531C using PCR-RFLP assay. Subsequently, promoter
and coding region of the LDLR gene was screened by PCR-
SSCP analysis and positive results were confirmed by DNA
sequencing. Four previously reported polymorphisms
1413G [ A, 1725C [ T, 1773T [ C and 2140 ? 5G [ A
were found in *17% (5/30) of population studied.
Moreover, no variation was found in APOB gene. Our data
indicated that LDLR and APOB gene mutations have not
contribution to possible FH in Iranian population studied
here. However, we examined three common APOB muta-
tions and LDLR in only 30 patients, and to determine the
role of these genes in developing FH in Iran, more FH
samples and populations needed to be investigated for the
mutations of the related genes.
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Introduction
Familial Hypercholesterolemia (FH; MIM# 143890) is a
common autosomal dominant disorder of lipoprotein
metabolism with a frequency of 1 in 500 of the heterozy-
gous and 1 in a million of homozygous form. FH is char-
acterized by elevations in LDL cholesterol, tendon
xanthomata, arcus cornea and increased risk of coronary
heart disease. The homozygous form of FH is much more
severe and depending on the type of mutation may cause
death in the early decades of life [1, 2]. Several different
factors may affect the manifestation of FH such as age,
gender, diet, type of LDLR mutations and other gene
mutations [3–5].
Mutation in the gene encoding the low-density lipo-
protein receptor (LDLR) is the most common genetic cause
of FH (http://www.ucl.ac.uk/fh). The LDL receptor protein
is a cell-surface protein which mediates specific uptake and
degradation of LDL by its endocytosis, mainly in liver. A
wide variety of mutations including insertions, deletions,
nonsense and missense mutations has been described in
patients with FH. LDLR gene (MIM# 606945) is located
on chromosome 19 (19p13.3) and consists of 18 exons
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which spans *45 kb with a mature protein of 860 amino
acids [6, 7].
Mutation in apolipoprotein B-100 gene (APOB100;
MIM 107730) is the second cause of the clinical FH phe-
notype. This gene is located on chromosome 2p24.1 that
codes for the protein component of LDL particles [8, 9].
ApoB-100 is an integral component of LDL and functions
as the ligand for the LDLR. Therefore mutations in the
APOB 100 will drastically alter its functional activity
leading to a decrease in its binding to LDLR, thereby
delaying the clearance of LDL particles. The latter situa-
tion usually results in a mild or severe form of hypercho-
lesterolemia together with an increased risk for early onset
atherosclerosis [10, 11]. In contrast to LDLR, only a small
number of functional mutations have been identified in
APOB gene such as R3500Q [12], R3500 W [13], and
R3531C [14]. There are very limited data regarding LDLR
and APOB gene mutations in Iranian population [15, 16].
The aim of this study was to characterize the LDLR and
three common apolipoprotein B 100 gene mutations in a
group of 30 non-related Iranian possible FH patients.
Materials and Methods
Subjects
Thirty unrelated possible FH subjects were included based
on the Dutch Lipid Clinic Network diagnostic criteria [17]
from the 92 suspected FH individuals referred to our affil-
iated clinics in Shahrekord University of Medical Sciences
in 2008. A total of 30 non-related Iranian possible FH
subjects were studied. All patients were taking lipid-low-
ering drug. Subjects (21 males and 9 females) were from
Chaharmahal va Bakhtiari province in southwest Iran with
high serum cholesterol [240 mg/dl and LDL choles-
terol [190 mg/dl aged between 29 and 73 years (mean:
55 years) (Table 1). All patients were clinically character-
ized and medical history were collected by a questionnaire.
Secondary causes of hypercholesterolemia were excluded,
such as diabetes mellitus (overnight fasting blood
sugar [126 mg dl-1), hypertension (systolic blood pres-
sure/diastolic blood pressure [140/90 mmHg), family his-
tory of premature coronary artery disease in first degree
relatives and smoking habit. Blood samples were collected
after obtaining informed consent from all patients. Glucose,
total cholesterol (TC) and triglycerides (TG) were assayed
using standard enzymatic procedures. HDL-C and LDL-C
were measured with direct method. The study protocol was
approved by the Review Board of the University.
Molecular Analyses
Genomic DNA was extracted from peripheral blood using
phenol–chloroform procedure.
All of the Primers for the LDLR and APOB gene were
designed using primer3 software. To exclude the APOB
mutations, all samples were initially tested for three APOB
gene mutations including R3500Q, R3500 W and R3531C
using PCR-RFLP assay. The Primer sequences and
restriction enzymes used for each mutation are shown in
Table 2.
Table 1 Clinical and
biochemical characteristics
of the patients studied
Parameters Patients (N = 30)
Mean ± SD
Men (N = 9)
Mean ± SD
Women (N = 21)
Mean ± SD
Age 55.10 ± 13.16 57.33 ± 17.93 54.14 ± 10.93
Sex 30 9 21
Total cholesterol (mg/dl) 302.93 ± 34.72 304.22 ± 47.27 302.38 ± 29.21
Triglycerides (mg/dl) 229.96 ± 112.05 242.55 ± 196.58 224.57 ± 51.46
HDL-cholesterol (mg/dl) 42.52 ± 13.07 40.00 ± 13.36 43.78 ± 13.25
LDL-cholesterol (mg/dl) 208.47 ± 26.59 210.50 ± 33.79 207.53 ± 24.12
Cholesterol/HDL ratio 7.47 ± 1.98 8.02 ± 2.44 7.19 ± 1.74
Table 2 PCR primers and restriction enzymes used for the APOB gene mutations analysis
Mutation Forward primer 50–30 Reverse primer 50–30 Size (bp) Res. enzyme
R3500Q CTTACTTTTCCATTGAGTACTCTACC AGTGCCCTGCAGCTTCACTGAGTAC 143 ScaI
R3500 W CTTACTTTTCCATTGATGCATC GTAAGTGGTTTTTCGTCATGTG 251 NlaIII
R3531C CTTACTTTTCCATTGATGCATC GTAAGTGGTTTTTCGTCATGTG 251 NsiI
The underlined nucleotides showing the mismatch bases created to introduce a new recognition site for each desired mutation providing a within-
assay control for the exclusion of false negative results
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The PCR amplification was performed at annealing
temperature of 64C using primers described in Table 2 in
a total volume of 25 ll. Ten micro liters of each PCR
product were digested overnight with 5 U (for NlaIII) and
10 U (for ScaI and NsiI) of restriction enzyme in a volume
of 20 ll. The digested products were separated on 6%
polyacrylamide gel at 40 mA for 1.5 h and visualized by
silver staining method.
To exclude the LDLR mutations, all of the 18 exons and
promoter region of the LDLR gene were PCR amplified at
annealing temperature of 51–67C. The Primer sequences
used for exons and promoter will be available in request.
The amplified products were then separated on 6%
polyacrylamide gel and visualized by silver staining
method. Following PCR amplification, 5 ll of PCR prod-
uct was mixed with 5 ll SSCP loading solution and was
made single stranded by heating at 95C for 10 min fol-
lowed by rapid chilling on ice. PCR-SSCP was carried out
using different gel concentration, component, current and
gel temperature (LDLR primers and PCR-SSCP conditions
will be available in request). Afterwards, the gels were
visualized by silver staining method. Fragments showing
mobility shifts of single strands were sequenced directly
using an ABI 3100 DNA Sequencer (Applied Biosystems).
Results
A total of 92 suspected FH individuals were investigated,
from which 30 possible FH subjects met the Dutch Lipid
Clinic Network diagnostic criteria (Table 1). All samples
were initially tested for three APOB gene mutations
including R3500Q, R3500 W and R3531C using PCR-
RFLP assay. None of the three APOB gene mutations
(R3500Q, R3500 W and R3531C) were detected in possi-
ble FH patients using PCR-RFLP assay. To exclude the
LDLR mutations, all of the 18 exons and promoter region
Fig. 1 Polyacrylamide gel of SSCP for exon 10. Lane 1 mobility
shifts of single strands, Lane 2–5 normal samples, Lane 6 double
strand PCR product, Lane 7 size marker
Fig. 2 Electropherograms of
LDLR gene polymorphisms
a 1413G [ A polymorphism,
b 1725 C [ T polymorphism,
c 1773 T [ C polymorphism,
d 2140 ? 5G [ A
polymorphism
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of the LDLR gene were examined using PCR-SSCP
strategy. However, four previously reported LDLR poly-
morphisms including 1413G [ A, 1725C [ T, 1773T [ C
and 2140 ? 5G [ A were found in 2, 1, 1 and 1 affected
individuals respectively. A gel picture of SSCP of exon 10
is showed in Fig. 1.
The polymorphisms 1413G [ A, 1725C [ T, 1773T [ C
and 2140 ? 5G [ A were found in 17% of patients from
which 1413G [ A and 1773T [ C were found in both allele
in 6 of 60 chromosomes (Fig. 2).
Discussion
The present study revealed four previously reported LDLR
gene polymorphisms including 1413G [ A, 1725C [ T,
1773T [ C and 2140 ? 5G [ A among 30 Iranian possi-
ble FH patients. LDLR gene polymorphisms were found in
17% of individuals studied. But no mutation was detected
in promoter and coding region of the LDLR gene studied.
Also none of the three APOB gene mutations including
R3500Q, R3500 W and R3531C were detected using PCR-
RFLP assay. This is similar to the very low detection rate
reported by other investigators that examined only one
exon [16] of the LDLR gene and one common mutation of
APOB (R3500Q) in 30 FH Iranian patients [15]. They
found one allelic variation (445G [ T) suggesting to be
possible mutation.
The frequency and variants of LDLR and APOB gene
mutations are different in populations.
The frequency of familial detective apolipoprotein
apoB100 (FDB) is estimated as (1/200) in central Europe
(e.g. Switzerland), decreasing gradually in Mediterranean
or Northern European populations. In Germany, UK and
USA, prevalence ranges from 1/700 to 1/500 [18, 19]. In
most countries in Europe in 3–5% of patients the hyper-
cholesterolemia is caused by a single mutation in the gene
for ApoB [20]. The R3500Q mutation could not be found
in Lebanon [21], Russia [22] and Turkey [23].
Mutations in the APOB gene were not detected in any of
our patients. A similar result was also obtained in a pre-
vious study in Iran [15]. Our finding about R3500Q
mutation is quite expected to the geographic distribution of
this mutation. In our present study, not finding any muta-
tion in APOB gene may be due to its low frequency rate.
A frequency of FH ranging from 1/411 (0.24%) for
North Karelians of Finland [24] to 1/67 (1.5%) for Ash-
kenazi Jew in South Africa [25]. The frequency of FH is
1/900 (0.11%) for Japanese in Asia [26]. Except one report
in Iranian HF patients, there is no report about the
molecular basis of FH in Iran. In this report [16] from 30
clinically diagnosed heterozygous FH patients, one new
variant (445G [ T) was reported. In a case report, an
Iranian boy with autosomal recessive hypercholesterolemia
was described too [27].
In present study, except four polymorphisms such as
1413G [ A, 1725C [ T, 1773C [ T and 2140 ? 5G [ A,
no mutation was found in exons studied. In total LDLR
gene alterations (polymorphisms) were found in 17% of
population studied. In our present study, not finding any
mutation maybe due to some factors:
1. In present study, no finding any mutation maybe due to
small number of patient. As we examined small
sample size of 30 patients, more samples must be
tested to reveal the contribution of this gene in causing
FH in Iranian families particularly in Chaharmahal va
Bakhtiari province.
2. In some patients, mutations may not be present in the
LDLR or APOB gene but occur in other genes such as
PCSK9 or in the unidentified FH3 gene on chromo-
some 1 [28].
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